SCHEMBL21101915

SCHEMBL21101915

CC(=N)NC(=O)Cc1cc(C(C)(C)F)cc(C(C)(F)F)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 3/20 0.36
PSEN1 P49768 2/20 0.34
PSEN2 P49810 2/20 0.34
APH1B Q8WW43 2/20 0.34
NCSTN Q92542 2/20 0.34
APH1A Q96BI3 2/20 0.34
PSENEN Q9NZ42 2/20 0.34
CYP2D6 P10635 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPT P10636 1/20 0.33
KDM4E B2RXH2 2/20 0.32
XBP1 P17861 1/20 0.32
ALOX12 P18054 1/20 0.32
HDAC1 Q13547 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
GBA1 P04062 1/20 0.31
SMN1; SMN2 Q16637 3/20 0.30
LMNA P02545 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21102124 0.84 RXRA (0.38) MEN1KMT2AKDM4ESMN1; SMN2LMNA
SCHEMBL21101912 0.80 TACR1 (0.35) TACR1PSEN1PSEN2APH1BNCSTN
SCHEMBL21101918 0.74 TACR1 (0.37) TACR1PSEN1PSEN2APH1BNCSTN
SCHEMBL16560482 0.70 CA2 (0.39) TACR1HTTCYP1A2CYP2C19
SCHEMBL21101764 0.69 CTSD (0.42) KMT2AKDM4E
SCHEMBL21102128 0.69 GLS (0.44) MEN1KMT2AMAPT
SCHEMBL21101917 0.66 KDM4E (0.55) MEN1KMT2AMAPTKDM4EALOX12
SCHEMBL21101913 0.65 MEN1 (0.34) TACR1CYP2D6MEN1KMT2ALMNA
Hydrochloric Acid SCHEMBL6208799 0.64 TACR1 (0.52) TACR1PSEN1PSEN2APH1BNCSTN
SCHEMBL8640586 0.63 TACR1 (0.55) TACR1PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019111225-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF NON‑ALCOHOLIC STEATOHEPATITIS AVALIV THERAPEUTICS (US) 2019-06-13 WO disclosed